- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06371768
Symptom Management and Transitioning to Engagement With Post-treatment Care for Adolescent and Young Adult Cancer Survivors (AYA STEPS)
April 15, 2024 updated by: Duke University
The purpose of this study is to determine the effectiveness of a digital health program called AYA STEPS, which is designed to help adolescent and young adult (AYA) cancer survivors manage symptoms and engage in recommended follow-up care.
Study Overview
Status
Not yet recruiting
Intervention / Treatment
Detailed Description
The investigators have developed an accessible digital health intervention, AYA STEPS (Symptom Management and Transitioning to Engagement with Post-Treatment Care for AYA Survivors), designed to enhance adolescent and young adult (AYA) cancer survivors' abilities to manage their high symptom burden and engage in follow-up health care.
Informed by the Obesity-Related Behavioral Intervention Trials (ORBIT) Model of intervention development, AYA STEPS has been systematically and rigorously developed and refined through the PI's prior work (K08CA245107).
AYA STEPS is organized into six remotely delivered sessions providing cognitive-behavioral and patient activation theory-based skills expected to lead to lower symptom burden and increased health care engagement by improving AYAs' self-efficacy for symptom management and activation.
The investigators propose a randomized controlled trial to examine the efficacy of AYA STEPS compared to AYA educational information for improving symptom burden and health care engagement for AYA survivors (N=260) who received cancer care in diverse health care settings (i.e., rural, urban, medically underserved areas) across North Carolina.
Self-efficacy and patient activation will be examined as mediators of intervention effects.
The planned study has the potential to produce clinically impactful health benefits for an underserved and understudied group of cancer survivors who have significant symptom burden, experience barriers to care engagement, and have limited access to AYA-specific behavioral interventions.
Study Type
Interventional
Enrollment (Estimated)
260
Phase
- Not Applicable
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Diagnosed with one of the following cancers: 1) stage I-III breast cancer; 2) stage I-III colorectal cancer; 3) stage I-III sarcoma; 4) stage I-III Hodgkin or non-Hodgkin lymphoma; or 5) stage I-II testicular cancer
- treated with curative intent and off therapy (with the exception of endocrine/hormonal therapy) for the last three months
- 1 to 5 years post-diagnosis
- Able to speak and read English
- Able to give informed consent
Exclusion Criteria:
- moderate or severe cognitive impairment
- severe untreated mental illness (e.g., schizophrenia, substance use disorder) that would interfere with providing meaningful consent/study participation
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Education Control
The education control condition will match AYA STEPS in delivery format [videoconferencing, web-based platform, frequency (biweekly sessions)], and session number (six) and length.
|
AYA-specific educational information is delivered using video conferencing by a clinical psychologist over six sessions.
Participants will receive a written manual providing tips for engaging with educational content as well as access to a website specific to the control arm, which will provide written, video, and pictorial information.
|
Experimental: AYA STEPS
Participants will receive the AYA STEPS digital health intervention, which includes six sessions delivered remotely (i.e., videoconferencing) by a clinical psychologist with intervention content accessed using a web-based platform.
|
The intervention provides cognitive-behavioral and patient activation theory-based skills designed to enhance AYA survivors' abilities to manage their high symptom burden and engage in follow-up health care.
Sessions with the psychologist will focus on enhancing participants' abilities to apply intervention skills and engage in the AYA STEPS digital health intervention using motivational interviewing, goal setting, and problem-solving techniques.
Participants will complete the six sessions over the 12 weeks of the AYA STEPS intervention.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pain severity and interference as measured by Brief Pain Inventory
Time Frame: Baseline, 3 Months, 6 Months, 12 Months
|
The Brief Pain Inventory will be used to assess pain severity and interference from pain across important life domains (e.g., general activity, work, relations with others).
This measures includes a body map on which the patient can mark the location(s) in which they are experiencing pain, as well as 8 questions on a scale of 0 to 10 with higher scores indicating worse pain severity or pain interference.
|
Baseline, 3 Months, 6 Months, 12 Months
|
Fatigue as measured by PROMIS Fatigue Scale
Time Frame: Baseline, 3 Months, 6 Months, 12 Months
|
Fatigue will be assessed using the Patient-Reported Outcomes Measurement Information System (PROMIS) Fatigue Scale, a 6-item self-report measure of fatigue.
Participants are asked to think about the last week when responding to each item (e.g., "In the past 7 days, how run-down did you feel, on average?"), providing ratings on a scale from "not at all" (1) to "very much" (5).
|
Baseline, 3 Months, 6 Months, 12 Months
|
Emotional distress as measured by PROMIS Depression Short Form
Time Frame: Baseline, 3 Months, 6 Months, 12 Months
|
Depressive symptoms will be assessed using the Patient-Reported Outcomes Measurement Information System (PROMIS) Depression Short Form, an 8-item measure assessing symptoms of depression in the last week.
Responses are on a 5-point scale from "never" (1) to "always" (5).
|
Baseline, 3 Months, 6 Months, 12 Months
|
Symptom interference as measured by MD Anderson Symptom Inventory (MDASI) Symptom Interference
Time Frame: Baseline, 3 Months, 6 Months, 12 Months
|
The MDASI will be used to assess interference of symptoms in daily living (e.g., working, relations with other people, enjoyment of life) over the past month.
The MDASI asks patients to rate the severity of 13 symptoms found frequently in patients with various cancers and treatment types on a scale from 0 (symptom "not present") to 10 (symptom "as bad as you can imagine").
This measure also includes 6 questions asking patients to rate the level of symptom interference in six domains (e.g., general activity, mood) on a scale from 0 (did not interfere) to 10 (interfered completely).
|
Baseline, 3 Months, 6 Months, 12 Months
|
Emotional distress as measured by PROMIS Anxiety Short Form
Time Frame: Baseline, 3 Months, 6 Months, 12 Months
|
Symptoms of Anxiety will be assessed using the Patient-Reported Outcomes Measurement Information System (PROMIS) Anxiety Short Form, an 8-item measure assessing symptoms of anxiety in the last week.
Responses are on a 5-point scale from "never" (1) to "always" (5).
|
Baseline, 3 Months, 6 Months, 12 Months
|
Health care engagement as measured by Patient Participation Questionnaire
Time Frame: Baseline, 3 Months, 6 Months, 12 Months
|
The Patient Participation Questionnaire will be used to assess participants' health care participation and associated domains (i.e., receipt of information, communication, perceptions of their relationship with the medical team).
Participants are asked to indicate their agreement with 17 items related to health care engagement on a 4 point scale: "to a great extent," "to some extent," "to a lesser extent," or "not at all."
An additional item asks patients about their overall assessment of their involvement in their healthcare.
|
Baseline, 3 Months, 6 Months, 12 Months
|
Patient self-assessment of communication competency with health care providers as measured by Medical Communication Competence Scale (MCCS) patient subscale
Time Frame: Baseline, 3 Months, 6 Months, 12 Months
|
The MCCS patient subscale will be used to assess survivors' perceptions of their competency for communicating and participating in health care.
The patient subscale includes 39 items on a scale of 1 to 7, with higher scores reflecting self-perception of better medical communication competence.
|
Baseline, 3 Months, 6 Months, 12 Months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Patient self-efficacy for chronic disease coping as measured by Self-Efficacy for Managing Chronic Illness Scale
Time Frame: Baseline, 3 Months, 6 Months, 12 Months
|
The 6-item Self-Efficacy for Managing Chronic Illness Scale will be used to assess participants' current confidence in their ability to prevent symptoms (e.g., pain, fatigue, distress) from interfering with life.
Responses are on a 10-point scale from "not at all confident" (1) to "totally confident" (10).
|
Baseline, 3 Months, 6 Months, 12 Months
|
Patient activation as measured by Patient Activation Measure (PAM)
Time Frame: Baseline, 3 Months, 6 Months, 12 Months
|
The PAM is a 13-item measure used to assess survivors' knowledge, skills, and confidence that are central to managing their health and health care.
Patients are asked to rate their agreement with statements about their health and health care on a 4 point scale from "strongly disagree" to "strongly agree."
From these response a total PAM score is calculated on a scale of 0-100, with higher scores indicating higher levels of activation.
|
Baseline, 3 Months, 6 Months, 12 Months
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Health care utilization: Chart Review
Time Frame: 12 Months
|
Health care utilization in the time since study enrollment will be assessed via review of participants' medical records to examine participants' receipt of general health screenings, cancer-related screenings, and follow-up care for late effects, in accordance with the 2024 National Comprehensive Cancer Network (NCCN) Adolescent and Young Adult (AYA) Guidelines.
|
12 Months
|
Area Deprivation Index (ADI)
Time Frame: Baseline
|
The ADI will be calculated using participants home mailing addresses.
The ADI is an indexed composite of 17 variables related to social determinants of health from the United States Census and American Community Survey that captures socioeconomic disadvantage at the census block group level.
The index is reported as a percentile from 0% to 100%, with higher scores indicating higher levels of deprivation.
|
Baseline
|
Health-care utilization: Self-report
Time Frame: Baseline, 3 Months, 6 Months, 12 Months
|
Participants' self-reports of their health care utilization since study enrollment will be collected to enhance the study team's ability to obtain chart review data.
|
Baseline, 3 Months, 6 Months, 12 Months
|
Health literacy as measured by Medical Term Recognition Test (METER)
Time Frame: Baseline
|
The METER will be used to assess health literacy.
Participants are asked to review a list of 40 words and check off those that they recognize as actual words.
|
Baseline
|
Participant experiences of discrimination as measured by Everyday Discrimination Scale-Short Form
Time Frame: Baseline
|
The Everyday Discrimination Scale-Short Form is a 5-item scale that assesses participants' subjective experiences of daily discrimination, with patients indicating the frequency of discrimination experiences on a 6-point scale from "never" to "almost everyday."
Patients who respond that they have experienced discrimination more frequently than "never" are asked what they think is the main reason(s) they experience(d) discrimination (e.g.
ancestry, gender, race).
|
Baseline
|
Participant evaluation of study mobile application as measured by User Version of the Mobile Application Rating Scale (uMARs)
Time Frame: 3 Months
|
The 20-item uMARs will be adapted to obtain participants' evaluation of the AYA STEPS digital health platform and the AYA Educational Information website.
Participants are asked to respond to questions regarding the quality of the mobile application on a 5-point scale from "inadequate" (1) to "excellent" (5).
A total quality score is calculated as the mean of four objective quality subscales (engagement, functionality, aesthetics, and information quality).
The uMARs also includes a subjective quality subscale.
|
3 Months
|
Satisfaction with Treatment and Interventionist as measured by the Satisfaction with Therapy and Therapist Scale-Revised (STTS-R)
Time Frame: 3 Months
|
Participants will complete the 13-item Satisfaction with Therapy and Therapist Scale-Revised specific to the interventionists delivering either AYA STEPS or AYA Educational Information.
The first 12 items ask participants to rate their agreement with statements related to intervention satisfaction on a 5-point scale ranging from "strongly disagree" (1) to "strongly agree" (5).
The 13th item asks "How much did the intervention help with your symptoms?"
with 5 answer choices ranging from "made things a lot better" to "made things a lot worse."
|
3 Months
|
Web-based Portal Use as measured by total time using portal in minutes
Time Frame: Continuous (Baseline to 12 Months)
|
The AYA STEPS web-based portal and AYA Education Information website will track overall participant usage and content access for each of the respective sessions.
The investigators will examine time spent accessing session content and time spent engaging in and completing home practice assignments.
|
Continuous (Baseline to 12 Months)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Estimated)
April 1, 2025
Primary Completion (Estimated)
June 30, 2029
Study Completion (Estimated)
June 30, 2029
Study Registration Dates
First Submitted
April 11, 2024
First Submitted That Met QC Criteria
April 15, 2024
First Posted (Actual)
April 17, 2024
Study Record Updates
Last Update Posted (Actual)
April 17, 2024
Last Update Submitted That Met QC Criteria
April 15, 2024
Last Verified
April 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Pro00115400
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
IPD Plan Description
It is the investigators' intention to make all data generated from this proposal freely available after it is de-identified.
All direct respondent identifiers (e.g., names and addresses) will be removed and maintained in a secure file for future contact purposes.
Respondent identifiers will not be shared.
All other scientific data (scale composites) will be both preserved and shared.
The following data will be preserved and shared: patient-reported data from study assessments, intervention utilization data collected via the study websites, healthcare utilization data collected from the health record, socio-demographic and medical data collected via patient report and health record, and scores on social determinant of health assessments (e.g., Area Deprivation Index).
The investigators will make every effort to provide raw data in a non-proprietary format wherever possible to enhance reproducibility.
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Sarcoma
-
Albert Einstein College of MedicineNational Cancer Institute (NCI)TerminatedUterine Corpus Leiomyosarcoma | Stage IIA Uterine Sarcoma | Stage IIB Uterine Sarcoma | Stage IIIA Uterine Sarcoma | Stage IIIB Uterine Sarcoma | Stage IIIC Uterine Sarcoma | Stage IVA Uterine Sarcoma | Stage IVB Uterine Sarcoma | Stage IA Uterine Sarcoma | Stage IB Uterine Sarcoma | Stage IC Uterine SarcomaUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)CompletedBone Sarcoma | Retroperitoneal Sarcoma | Adult Soft Tissue SarcomaUnited States
-
Mohammed M MilhemGenentech, Inc.CompletedSarcoma | Soft Tissue Sarcoma | Metastatic Sarcoma | Locally Advanced Sarcoma | Unresectable SarcomaUnited States
-
National Cancer Institute (NCI)RecruitingMetastatic Alveolar Soft Part Sarcoma | Unresectable Alveolar Soft Part Sarcoma | Advanced Soft Tissue Sarcoma | Advanced Alveolar Soft Part SarcomaUnited States
-
National Cancer Institute (NCI)RecruitingMetastatic Leiomyosarcoma | Unresectable Leiomyosarcoma | Metastatic Sarcoma | Unresectable Soft Tissue Sarcoma | Metastatic Soft Tissue Sarcoma | Unresectable SarcomaUnited States
-
National Cancer Institute (NCI)CompletedRhabdomyosarcoma | Synovial Sarcoma | Ewing's Sarcoma | MPNST | High-risk SarcomaUnited States
-
Epizyme, Inc.RecruitingAdvanced Soft-tissue Sarcoma | Advanced Epithelioid SarcomaUnited States, Taiwan, Canada, United Kingdom
-
Brown UniversityActuate Therapeutics Inc.WithdrawnSoft Tissue Sarcoma | Osteosarcoma | Ewing Sarcoma of Bone | Leiomyosarcoma | High Grade Sarcoma | Liposarcoma | Rhabdomyosarcoma | Angiosarcoma | Bone Sarcoma | Synovial Sarcoma | Undifferentiated Pleomorphic Sarcoma | Myxofibrosarcoma | Spindle Cell SarcomaUnited States
-
Centre Oscar LambretFrench Sarcoma Group; Study Group of Bone TumorsCompletedSoft Tissue Sarcoma | Uterine SarcomaFrance
-
Advenchen Laboratories, LLCActive, not recruitingLeiomyosarcoma | Synovial Sarcoma | Alveolar Soft Part Sarcoma | Soft-Tissue SarcomaUnited States, United Kingdom, Spain, China, Italy
Clinical Trials on AYA Educational Information
-
Dana-Farber Cancer InstituteNational Cancer Institute (NCI)Recruiting
-
Columbia UniversityCompleted
-
Rutgers, The State University of New JerseyCompleted
-
Columbia UniversityCompleted
-
Riphah International UniversityNot yet recruitingPrimary DysmenorrheaPakistan
-
Children's Memorial Health Institute, PolandSiemens Healthcare Sp. z o.o.RecruitingDemyelinating Diseases | Urinary Incontinence | Brain Tumor | Headache | Visual Impairment | Growth Deficiency | Psychomotor Retardation, Mild to SeverePoland
-
Northwestern UniversityCompleted
-
University of Missouri-ColumbiaCompletedPhysical Inactivity | Poor DietUnited States
-
Parc de Salut MarCompletedTotal Knee ReplacementSpain
-
University Hospital, Clermont-FerrandInnovatherm; Clermont CommunautéCompletedPhysical Activity | Knee Osteoarthritis | Exercise | Education | Self-managementFrance